ABSTRACT

Various reports regarding hematospermia are available in the literature. In our series, the incidence of hematospermia seems to be quite low. This might result due to the high experience of our institution regarding the procedure as well as the sociocultural background of the patients. Counseling the patients and monitoring them in terms of possible complications after TRUS-bx is essential.

The mean age, serum total PSA level, and prostate volume were 65.1 (44–81) years, 7.8 ng/mL (2.6–142) ng/mL, and 43.0 cc (22–238), respectively. Hematospermia was detected in 82 (6.7%) patients.

Totally, 1210 patients with clinical suspicion of prostate cancer due to abnormality on the digital rectal examination or rising of prostatic-specific antigen, in whom the TRUS-bx was performed, were included in the study. All patients were given antibiotic prophylaxis before the procedure. One week and 4 weeks after the biopsy, the patients were called to the clinic for evaluating the biopsy complications.

Transrectal ultrasound-guided prostate biopsy (TRUS-Bx) is the gold standard method for detecting prostate cancer. It is generally a well-tolerated procedure with low risk of major complications. However, minor complications are frequent. In this study, the incidence of hematospermia after TRUS prostate biopsy was evaluated.